Pfizer Inc. / Allergan plc

Eye Care / Dry Eye Disease

16M US cases/yr · $5.2B US Ophthalmic Rx Market (2015)

Disease Overview

Dry eye disease affects ~16.4 million Americans and arises from inadequate tear production, excessive evaporation, or poor tear quality, causing ocular surface inflammation. Risk rises with age >50, female sex, contact-lens wear, screen use, and autoimmune conditions such as Sjögren syndrome. Untreated severe disease can damage the cornea.

Competitive Landscape

In 2015, Allergan held dominant share in the prescription eye care market, particularly in dry eye (Restasis) and glaucoma (Lumigan). The landscape was beginning to shift as biosimilar and generic competition loomed, and Novartis/Alcon and Bausch+Lomb competed aggressively in surgical ophthalmology.

Womens Health

Competitive Landscape

Lo Loestrin Fe (norethindrone acetate/ethinyl estradiol/ferrous fumarate) competes in the crowded combined hormonal contraceptive (CHC) market, where differentiation rests on estrogen dose, progestin chemistry, and regimen. Low-dose ethinyl estradiol (EE) CHCs: Lo Loestrin Fe's 10 mcg EE dose is the lowest among branded combined oral contraceptives; Minastrin 24 Fe (norethindrone/EE 20 mcg) and Loestrin 24 Fe are closest branded analogues. Drospirenone-containing CHCs: Yaz and Yasmin (drospirenone/EE, Bayer) and Beyaz (with levomefolate) are major branded competitors with anti-androgenic positioning; Nextstellis (drospirenone/estetrol, Mayne Pharma) introduced the first novel native estrogen E4 in 2021. Extended/continuous-cycle CHCs: Seasonique and LoSeasonique (levonorgestrel/EE, Teva) offer quarterly withdrawal bleeding. Norgestimate-based CHCs: Ortho Tri-Cyclen Lo (norgestimate/EE 25 mcg, Janssen) and numerous generics dominate volume share. Non-oral hormonal contraceptives: the etonogestrel vaginal ring NuvaRing/Annovera (Mayne), transdermal patch Xulane/Twirla (norelgestromin-EE or levonorgestrel-EE), and Nexplanon implant (Organon) are alternative-route CHCs/progestin-only options. Generic low-dose EE combinations and progestin-only pills (Opill, now OTC in the US) represent significant price-based substitution. For a commercial lead, Lo Loestrin's franchise durability rests on the 10 mcg EE positioning versus generic erosion.

Gastroenterology

Competitive Landscape

Viberzi (eluxadoline) competes in IBS-with-diarrhea (IBS-D) and broader functional GI disorders, where treatment is fragmented across distinct MOA classes. Mixed opioid receptor modulators: eluxadoline (Viberzi) is the only FDA-approved mu-agonist/delta-antagonist; no direct MOA analogue is marketed. Non-absorbable antibiotics: rifaximin (Xifaxan, Salix/Bausch) is FDA-approved for IBS-D and is the dominant branded alternative, with a repeat-treatment label. 5-HT3 antagonists: alosetron (Lotronex) is approved for severe IBS-D in women under a REMS program, restricting uptake. Antispasmodics/anticholinergics: dicyclomine (Bentyl) and hyoscyamine remain inexpensive generic incumbents used broadly off-label in IBS-D. Tricyclic antidepressants: low-dose amitriptyline and nortriptyline are guideline-recommended for visceral pain in IBS and used off-label. Bile-acid sequestrants: cholestyramine (Questran) and colesevelam (Welchol) are used off-label in bile-acid diarrhea, a subset of IBS-D. Loperamide (Imodium), an OTC mu-opioid agonist, is a near-universal first-line antidiarrheal and a persistent price anchor. For a commercial lead, Viberzi's franchise threat is bounded primarily by Xifaxan's scale and generic competition; a 2017 FDA Drug Safety Communication contraindicated Viberzi in patients without a gallbladder, materially constraining addressable IBS-D population.

Neurosciences / CNS

Competitive Landscape

Botox Therapeutic (onabotulinumtoxinA) leads the neurotoxin franchise across chronic migraine, cervical dystonia, spasticity, and overactive bladder, with competitors segmented by serotype and formulation. Type A botulinum neurotoxins (direct therapeutic substitutes): abobotulinumtoxinA (Dysport, Ipsen/Galderma), incobotulinumtoxinA (Xeomin, Merz), and prabotulinumtoxinA (Jeuveux, Evolus) are FDA-approved; Dysport and Xeomin carry broad therapeutic labels in cervical dystonia and spasticity, while Jeuveux is cosmetic-only. DaxibotulinumtoxinA (Daxxify, Revance) is FDA-approved for cervical dystonia and glabellar lines with a longer-duration profile. Type B neurotoxins: rimabotulinumtoxinB (Myobloc, Supernus) is approved for cervical dystonia and chronic sialorrhea, used largely in toxin-A-resistant patients. CGRP-pathway migraine preventives are the primary cross-MOA threat in chronic migraine: erenumab (Aimovig, Amgen/Novartis), fremanezumab (Ajovy, Teva), galcanezumab (Emgality, Lilly), and eptinezumab (Vyepti, Lundbeck) are FDA-approved anti-CGRP/CGRP-receptor monoclonals; oral gepants atogepant (Qulipta, AbbVie) and rimegepant (Nurtec ODT, Pfizer) extend preventive options. In overactive bladder, beta-3 agonists mirabegron (Myrbetriq, Astellas) and vibegron (Gemtesa, Urovant) and antimuscarinics compete before Botox is considered. Botox remains category-dominant at multi-billion-dollar annual sales per AbbVie 10-K disclosures.